Abstract: A pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, and an immunomodulatory moiety bound to at least a portion of the cationic layer. Alternatively, the pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, an anionic layer disposed on at least a portion of the cationic layer, and an immunomodulatory moiety bound to at least a portion of the anionic layer.

Abstract: An encapsulated living (viable) mammalian cell, and methods of making and using that cell, are provided.

Abstract: A method to prepare a population of metal-organic polyhedra (MOP) supported micelle nanoparticles (NPs), and a composition comprising MOP supported micelle NPs, are provided.

Abstract: A pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, and an immunomodulatory moiety bound to at least a portion of the cationic layer. Alternatively, the pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, an anionic layer disposed on at least a portion of the cationic layer, and an immunomodulatory moiety bound to at least a portion of the anionic layer.

Abstract: Disclosed are methods of preparing a porous ceramic support for an ultra-thin enzyme-assisted membrane, and a new membrane that can be used for gas filtration purposes to remove/separate carbon dioxide or other gases from a gas mixture such as those from power production or enhanced oil recovery or fuel production or air, and recycle/collect/utilize carbon dioxide. In some embodiments, a method may include blocking the pores of a porous substrate with a removable medium, and polishing the surface, coating a silica sol-gel solution onto the support, and removing the blocking medium and sol-gel surfactant to leave a well-confined porous structure.

Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.

Abstract: In one aspect, a method generally includes obtaining a dried silicified cell that has been stored for at least 24 hours without cryopreservation and rehydrating the dried silicified cell in a pharmaceutically acceptable carrier. The method can further include surface modifying the silicified cell with at least one immunogenic molecule. The method can further include administering the rehydrated silicified cell to a subject. In some embodiment, the dried silicified cell has been stored for at least 14 days without cryopreservation. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject a chemotherapeutic agent effective to treat the tumor and administering to the subject a silicified cell vaccine effective to treat the tumor.

Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.

Abstract: A silicified cell includes a nanoparticle that carries a bioactive agent. The silicified call can be a tumor cell, a bacterial cell, a virus, or a silicifiable compartment or fragment thereof. The silicified cell can optionally include an immunomodulatory moiety that may be carried within pores of the nanoparticle and/or bound to the surface of the nanoparticle. The silicified cell can be used as a prophylactic or therapeutic treatment for treating tumors or bacterial infections.

Abstract: A mesoporous silica nanoparticle includes a plurality of pores, a bioactive agent disposed in at least a portion of the ores, and an immunomodulatory moiety either disposed in a portion of the pores or bound to at least a portion of the outer surface of the nanoparticle.

Abstract: A method to prepare a population of metal-organic polyhedra (MOP) supported micelle nanoparticles (NPs), and a composition comprising MOP supported micelle NPs, are provided.

Abstract: A pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, and an immunomodulatory moiety bound to at least a portion of the cationic layer. Alternatively, the pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, an anionic layer disposed on at least a portion of the cationic layer, and an immunomodulatory moiety bound to at least a portion of the anionic layer.

Abstract: An encapsulated living (viable) mammalian cell, and methods of making and using that cell, are provided.

Abstract: A modified vertebrate cell comprising a vertebrate cell encased in reversibly interlinked metal-organic framework (MOF) nanoparticles, and methods of making and using the modified cell, are provided.

Abstract: Zr-based MOF NPs for cryopreservation of cells including, for example, red blood cells.

Abstract: Methods of preparing red blood cell mimetics and functionalized red blood cell mimetics, and methods of making and using those mimetics, are provided.

Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.